INmune Bio (NASDAQ:INMB) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of INmune Bio (NASDAQ:INMB) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings lowered INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

INmune Bio Trading Up 9.2%

INMB stock opened at $2.08 on Friday. The firm has a 50 day moving average of $1.63 and a 200-day moving average of $1.48. The company has a market cap of $55.42 million, a price-to-earnings ratio of -3.11 and a beta of 0.97. INmune Bio has a 12-month low of $1.09 and a 12-month high of $2.61.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16.

Institutional Trading of INmune Bio

Several large investors have recently modified their holdings of the business. Royal Bank of Canada raised its position in shares of INmune Bio by 44.8% during the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after purchasing an additional 9,236 shares during the last quarter. Jane Street Group LLC acquired a new stake in INmune Bio during the 1st quarter valued at $142,000. Rhumbline Advisers increased its position in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after buying an additional 2,409 shares in the last quarter. Geode Capital Management LLC increased its position in INmune Bio by 6.9% during the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after buying an additional 25,069 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of INmune Bio in the second quarter worth $26,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.